人工肝和干细胞在肝衰竭治疗中的进展

何宏亮; 李建国; 高志良

doi:10.3969/j.issn.1001-5256.2013.09.009

人工肝和干细胞在肝衰竭治疗中的进展

DOI: 10.3969/j.issn.1001-5256.2013.09.009

中山大学附属第三医院感染性疾病科

基金项目:

“十二五”国家科技重大专项(2012ZX10002004)；

详细信息

中图分类号: R575.3
计量
- 文章访问数: 3097
- HTML全文浏览量: 23
- PDF下载量: 740
- 被引次数: 0
出版历程
- 收稿日期: 2013-06-26
- 出版日期: 2013-09-20

Investigation of artificial liver support system combined with stem cell transplantation in treatment of liver failure

Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat - sen University

Research funding:

摘要

摘要: 目前肝衰竭的治疗手段主要包括内科综合治疗、人工肝支持系统治疗、肝移植和干细胞移植等,近些年人工肝支持系统和干细胞移植在肝衰竭治疗方面取得了较大的进展。介绍了临床上常用的非生物型人工肝治疗方法和生物型人工肝的细胞来源、细胞培养方式、生物反应器及临床应用等。探讨了干细胞治疗肝衰竭的机制和临床应用。针对人工肝和干细胞治疗肝衰竭临床疗效欠佳的问题,提出了两者联合治疗肝衰竭的可行性。
- 肝,人工 /
- 干细胞 /
- 肝功能衰竭
Abstract: Currently, the main treatment strategies for liver failure include comprehensive medical treatment, artificial liver support system treatment, liver transplantation, and stem cell transplantation. In recent years, major progress has been made in liver failure treatment with artificial liver support system and stem cell transplantation. Non- bioartificial liver treatments commonly seen in the clinical setting, as well as the cell source, cell culture method, bioreactor, and clinical application of bioartificial liver, are reviewed. The mechanism and clinical application of stem cell therapy for liver failure are discussed. In view of the unsatisfactory clinical effect of artificial liver or stem cells alone in the treatment of liver failure, the feasibility of combination therapy with artificial liver and stem cells for liver failure is proposed.
- liver, artificial /
- stem cells /
- liver failure

HTML全文

参考文献(20)

[1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Diagnostic and treatment guidelines for liver failure[J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南[J].中华临床感染病杂志, 2012, 5 (6) :321-327.

[2]YE YN, GAO ZL.Three attacks in the development of HBV-related liver failure[J].Infect Dis Info, 2009, 22 (5) :276-279. (in Chinese) 叶一农, 高志良.乙型肝炎肝衰竭发生机制中的三重打击[J].传染病信息, 2009, 22 (5) :276-279.

[3] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.Non biological artificial liver support system treatment guidelines for liver failure[J].Chin J Clin Infect Dis, 2009, 2 (6) :321-325. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组.非生物型人工肝支持系统治疗肝衰竭指南[J].中华临床感染病杂志, 2009, 2 (6) :321-325.

[4]LI LJ, LIU XL, XU XW, et al.Comparison of plasma exchange with different membrane pore sizes in the treatment of severe viral hepatitis[J].Ther Apher Dial, 2005, 9 (5) :396-401.

[5]HASSANEIN T, BLEI AT, PERRY W, et al.Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy[J].Am J Gastroenterol, 2009, 104 (6) :1392-1400.

[6]BANARES R, NEVENS F, LARSEN FS, et al.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure:the RELIEF trial[J].Hepatology, 2013, 57 (3) :1153-1162.

[7]KRIBBEN A, GERKEN G, HAAG S, et al.Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure[J].Gastroenterology, 2012, 142 (4) :782-789.

[8] LEE KD, KUO TK, WHANG-PENG J, et al.In vitro hepatic differentiation of human mesenchymal stem cells[J].Hepatology, 2004, 40 (6) :1275-1284.

[9]BANAS A, TERATANI T, YAMAMOTO Y, et al.Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes[J].Hepatology, 2007, 46 (1) :219-228.

[10] AURICH I, MUELLER LP, AURICH H, et al.Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers[J].Gut, 2007, 56 (3) :405-415.

[11]GERLACH JC, MUTIG K, SAUER IM, et al.Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors:a morphologic study[J].Transplantation, 2003, 76 (5) :781-786.

[12]LECKIE P, DAVENPORT A, JALAN R.Extracorporeal liver support[J].Blood Purif, 2012, 34 (2) :158-163.

[13]PODOLL AS, de GOLOVINE A, FINKEL KW.Liver support systems-a review[J].ASAIO J, 2012, 58 (5) :443-449.

[14]DOMINICI M, Le BLANC K, MUELLER I, et al.Minimal criteria for defining multipotent mesenchymal stromal cells.The International Society for Cellular Therapy position statement[J].Cytotherapy, 2006, 8 (4) :315-317.

[15]ARIKURA J, INAGAKI M, HUILING X, et al.Colonization of albumin-producing hepatocytes derived from transplanted F344 rat bone marrow cells in the liver of congenic Nagase's analbuminemic rats[J].J Hepatol, 2004, 41 (2) :215-221.

[16]JU S, TENG GJ, LU H, et al.In vivo differentiation of magnetically labeled mesenchymal stem cells into hepatocytes for cell therapy to repair damaged liver[J].Invest Radiol, 2010, 45 (10) :625-633.

[17] De MIGUEL MP, FUENTES-JULIN S, BLZQUEZ-MARTNEZ A, et al.Immunosuppressive properties of mesenchymal stem cells:advances and applications[J].Curr Mol Med, 2012, 12 (5) :574-591.

[18]DAI LJ, LI HY, GUAN LX, et al.The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis[J].Stem Cell Res, 2009, 2 (1) :16-25.

[19] PENG L, XIE DY, LIN BL, et al.Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B:short-term and long-term outcomes[J].Hepatology, 2011, 54 (3) :820-828.

[20]PENG L, LI H, GU L, et al.Comparison of biological characteristics of marrow mesenchymal stem cells in hepatitis B patients and normal adults[J].World J Gastroenterol, 2007, 13 (11) :1743-1746.

施引文献

资源附件(0)

访问统计